GlassScriptPhysician profile
David J Fitzhugh
NPI 1962627547
$103,514.48
in general payments reported to CMS, 2019-2025
36 companies · $33K in 2025
The $33K reported for 2025 was more than what 94% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $2,091 · 2021: $14K · 2022: $6,129 · 2023: $10K · 2024: $37K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Food and Beverage: $7,189 · Travel and Lodging: $6,769 · Consulting Fee: $3,617 · Honoraria: $3,320 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,935.00 |
| Food and Beverage | $7,189.41 |
| Travel and Lodging | $6,769.31 |
| Consulting Fee | $3,617.29 |
| Honoraria | $3,320.00 |
| Education | $155.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $46,428.57 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genentech USA, INC. | $38,935.51 | 2019-2025 | Xolair |
| Alk-Abello, INC | $4,603.17 | 2020-2025 | Odactra, Standardized Mite D. Farinae, Timothy, Standardized |
| Aimmune Therapeutics, INC. | $3,200.86 | 2021 | |
| Glaxosmithkline, LLC. | $1,990.78 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $1,966.64 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $1,391.17 | 2021-2025 | Takhzyro, Eohilia, Hyqvia |
| Biocryst US Sales Co., LLC | $1,319.52 | 2021-2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $654.66 | 2021-2025 | Dupixent |
| Genzyme Corporation | $509.72 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $414.09 | 2019-2025 | |
| Abbvie INC. | $413.47 | 2022-2025 | |
| Amgen INC. | $347.51 | 2021-2025 | Tezspire |
| Grifols USA, LLC | $183.25 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Optinose US, INC. | $172.15 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $159.21 | 2023-2024 | Ayvakit |
| Organon LLC | $117.72 | 2025 | Vtama |
| Pfizer INC. | $107.38 | 2019-2023 | |
| Pharming Healthcare, INC. | $101.32 | 2020-2025 | Ruconest |
| Incyte Corporation | $71.45 | 2021-2022 | |
| Covis Pharma Gmbh | $53.13 | 2021-2022 | |
| Kaleo, INC. | $45.23 | 2019-2023 | Auvi-Q |
| Biocryst Pharmaceuticals, INC. | $37.81 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $35.97 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.67 | 2019-2023 | Spiriva |
| Ionis Pharmaceuticals, INC. | $32.03 | 2025 | Dawnzera |
| Adma Biomanufacturing LLC | $24.17 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $23.33 | 2019-2020 | |
| Phadia US INC. | $21.30 | 2021 | |
| Octapharma USA, INC. | $21.01 | 2021 | |
| Merck Sharp & Dohme LLC | $17.78 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.13 | 2020 | |
| Genentech, INC. | $16.93 | 2024 | Xolair |
| Arcutis Biotherapeutics, INC. | $16.92 | 2025 | Zoryve |
| Uswm, LLC | $16.00 | 2021 | |
| Hikma Pharmaceuticals USA | $13.92 | 2025 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fitzhugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.